Trupanion Inc (NYSE:TRUP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm currently has a $19.00 price target on the stock. Zacks Investment Research’s price target would indicate a potential upside of 13.43% from the stock’s current price.

According to Zacks, “Trupanion, Inc. operates as a direct-to-consumer monthly subscription service provider of a medical insurance plan for cats and dogs. It operates primarily in Canada, Puerto Rico, and the United States. The Company serves pet owners and veterinarians. Trupanion, Inc. is headquartered in Seattle, Washington. “

A number of other equities research analysts have also recently weighed in on the company. RBC Capital Markets restated an “outperform” rating and issued a $18.00 price target (up previously from $14.00) on shares of Trupanion in a research note on Wednesday, August 3rd. Canaccord Genuity restated a “buy” rating and issued a $19.00 price target on shares of Trupanion in a research note on Thursday, August 4th. Finally, Stifel Nicolaus increased their price target on Trupanion from $17.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, August 3rd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Trupanion has a consensus rating of “Buy” and a consensus target price of $16.00.

Analyst Recommendations for Trupanion (NYSE:TRUP)

Trupanion (NYSE:TRUP) opened at 16.75 on Tuesday. Trupanion has a one year low of $7.61 and a one year high of $17.68. The firm’s 50 day moving average price is $16.12 and its 200-day moving average price is $15.19. The company’s market capitalization is $489.99 million.

Trupanion (NYSE:TRUP) last posted its quarterly earnings results on Tuesday, November 1st. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). The business earned $48.40 million during the quarter, compared to the consensus estimate of $48.17 million. During the same quarter last year, the company posted ($0.17) EPS. The firm’s revenue was up 27.7% on a year-over-year basis. Equities analysts forecast that Trupanion will post ($0.23) earnings per share for the current fiscal year.

In other news, Director Howard E. Rubin sold 21,249 shares of the stock in a transaction on Wednesday, November 23rd. The stock was sold at an average price of $17.01, for a total transaction of $361,445.49. Following the sale, the director now directly owns 41,294 shares of the company’s stock, valued at approximately $702,410.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Darryl Rawlings sold 3,500 shares of the stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $16.21, for a total value of $56,735.00. Following the sale, the chief executive officer now directly owns 1,526,505 shares in the company, valued at $24,744,646.05. The disclosure for this sale can be found here.

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Advisors LLC raised its stake in Trupanion by 88.0% in the third quarter. BlackRock Advisors LLC now owns 8,616 shares of the company’s stock valued at $146,000 after buying an additional 4,032 shares during the period. AQR Capital Management LLC acquired a new stake in Trupanion during the second quarter valued at $146,000. The Manufacturers Life Insurance Company acquired a new stake in Trupanion during the third quarter valued at $194,000. Metropolitan Life Insurance Co. NY acquired a new stake in Trupanion during the second quarter valued at $160,000. Finally, A.R.T. Advisors LLC acquired a new stake in Trupanion during the second quarter valued at $166,000.

WARNING: “Trupanion Inc (TRUP) Rating Increased to Buy at Zacks Investment Research” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/24/trupanion-inc-trup-rating-increased-to-buy-at-zacks-investment-research.html.

Trupanion Company Profile

Trupanion, Inc provides a medical insurance plan for cats and dogs across the United States, Canada and Puerto Rico. The Company operates through two segments: subscription business and other business. The subscription business segment includes monthly subscriptions related to the Company’s medical plan, which are marketed directly to consumers.

5 Day Chart for NYSE:TRUP

Receive News & Stock Ratings for Trupanion Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion Inc and related stocks with our FREE daily email newsletter.